ELSAN
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ELSAN - overview
Established
2015
Location
Paris, -, France
Primary Industry
Healthcare
About
Based in Paris, France, and founded in 2015 from the merger between Vedici and Vitalia groups, Groupe ELSAN, aka ELSAN (formerly Vedici) operates as a healthcare company that offers medicine, surgery, cancer treatments, cardiology, obstetrics, and diagnostic services. In July 2020, KKR, CVC Capital Partners, Tethys Invest, and Ardian agreed to acquire a 70% majority stake in ELSAN for approximately EUR 3 billion. ELSAN offers cancer treatment, algology, dental surgery, oral surgery, pediatric surgery, vascular surgery, dermatology, dietetics, gynecology, hematology, nuclear medicine, vascular medicine, obstetrics, pediatrics, and cardiology, as well as diagnosis. The company also offers personalized support for maternities, dom service.
The company gives hospitality and personalized services that include hotel, ambulatory, and restoration. In addition, the company offers ADEL, an ELSAN digital assistant, a mobile application that offers its users services and features to simplify many procedures related to their health.
Current Investors
Ardian, KKR, CVC
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Hospitals, Cardiology, Oncology/Cancer Treatment
Website
www.elsan.care/fr
Verticals
Mobile Apps
Company Stage
Mature
Total Amount Raised
Subscriber access only
ELSAN - timeline of key events
ELSAN - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 111,019,503 | 23,287,644 | 37,463,150 | 43,085,430 | 42,757,065 | 56,885,214 | - | - | - |
| % Revenue Growth (YoY) | - | (79.0%) | 60.9% | 15.0% | (0.8%) | 33.0% | - | - | - |
| EBITDA (USD) | 21,857,591 | 5,614,340 | (14,683,957) | 36,297,062 | 22,018,007 | 31,214,372 | - | - | - |
| Operating Income (USD) | 20,720,584 | 3,974,398 | (18,523,024) | 33,631,992 | 20,005,858 | 25,603,616 | - | - | - |
| Operating Margin | 18.7% | 17.1% | (49.4%) | 78.1% | 46.8% | 45.0% | - | - | - |
| % EBITDA Margin | 19.7% | 24.1% | (39.2%) | 84.2% | 51.5% | 54.9% | - | - | - |
| NET Income (USD) | 13,997,460 | (7,140,548) | (42,414,853) | 21,331,930 | (6,868,210) | 25,652,190 | - | - | - |
| % Net Margin | 12.6% | (30.7%) | (113.2%) | 49.5% | (16.1%) | 45.1% | - | - | - |
ELSAN - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N/A | Completed | Clinique du Cambrésis, Clinique du Sud, Clinique les Lauriers, Clinique Supervaltech, Clinique Valdegour | - | ||||||||
| N/A | Completed | - | |||||||||
| Add-on, Trade Sale | Completed | Groupe C2S SAS | - | ||||||||
| Secondary Buyout | Completed | ELSAN | - | ||||||||
| Trade Sale | Completed | ELSAN | - |
Displaying 1 - 5 of 15
ELSAN - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.